Accelerating Medicines Partnership® SCHIZOPHRENIA
The Accelerating Medicines Partnership (AMP®) Schizophrenia (SCZ) program aims to clarify the disease pathways and long-term outcomes of people who are at risk for schizophrenia and to identify new and better targets for early treatment.



The Accelerating Medicines Partnership (AMP®) program is a public-private partnership between the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), pharmaceutical and life science companies, non-profits and other organizations. The overarching aim of the AMP program is to improve our understanding of disease pathways and identify new and better targets for treatment. 

The AMP Schizophrenia (SCZ) program was launched in 2020 to address the critical need for more effective treatments for people with schizophrenia and related mental health conditions. 

The AMP SCZ Program Approach

The aims of this 5-year $99.4 million global effort include developing tools that identify the early stages of risk for schizophrenia and predicting the likelihood of progression to psychosis and other outcomes. A related aim is to develop tools that can help researchers identify new targets for drug-based treatments that can be tested in clinical trials. 

The AMP SCZ program is managed by the Foundation for the National Institutes of Health (FNIH). More detailed information about the AMP SCZ program is available on the FNIH website.

Last Reviewed on May 2, 2022